Literature DB >> 21316497

Management of hepatitis C virus genotype 4: recommendations of an international expert panel.

Mahmoud A Khattab1, Peter Ferenci, Stephanos J Hadziyannis, Massimo Colombo, Michael P Manns, Piero L Almasio, Rafael Esteban, Ayman A Abdo, Stephen A Harrison, Nazir Ibrahim, Patrice Cacoub, Mohammed Eslam, Samuel S Lee.   

Abstract

HCV has been classified into no fewer than six major genotypes and a series of subtypes. Each HCV genotype is unique with respect to its nucleotide sequence, geographic distribution, and response to therapy. Genotypes 1, 2, and 3 are common throughout North America and Europe. HCV genotype 4 (HCV-4) is common in the Middle East and in Africa, where it is responsible for more than 80% of HCV infections. It has recently spread to several European countries. HCV-4 is considered a major cause of chronic hepatitis, cirrhosis, hepatocellular carcinoma, and liver transplantation in these regions. Although HCV-4 is the cause of approximately 20% of the 170 million cases of chronic hepatitis C in the world, it has not been the subject of widespread research. Therefore, this document, drafted by a panel of international experts, aimed to review current knowledge on the epidemiology, natural history, clinical, histological features, and treatment of HCV-4 infections.
Copyright © 2010 European Association for the Study of the Liver. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21316497     DOI: 10.1016/j.jhep.2010.11.016

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  40 in total

Review 1.  Treatment of non-genotype 1 hepatitis C virus patients.

Authors:  Alessandra Mangia; Leonardo Mottola
Journal:  Curr Gastroenterol Rep       Date:  2012-02

2.  Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome: an accelerated approach toward epitope-driven vaccine development.

Authors:  Karim M Abdel-Hady; Andres H Gutierrez; Frances Terry; Joe Desrosiers; Anne S De Groot; Hassan M E Azzazy
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

3.  Performance evaluation of the new Roche cobas AmpliPrep/cobas TaqMan HCV test, version 2.0, for detection and quantification of hepatitis C virus RNA.

Authors:  S Pas; R Molenkamp; J Schinkel; S Rebers; C Copra; S Seven-Deniz; D Thamke; R J de Knegt; B L Haagmans; M Schutten
Journal:  J Clin Microbiol       Date:  2012-11-14       Impact factor: 5.948

4.  Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study.

Authors:  O Anagnostou; S Manolakopoulos; G Bakoyannis; G Papatheodoridis; A Zisouli; M Raptopoulou-Gigi; E Manesis; I Ketikoglou; G Dalekos; C Gogos; T Vassiliadis; D Tzourmakliotis; S Karatapanis; S Kanatakis; - Zoumpoulis; A Hounta; S Koutsounas; G Giannoulis; N Tassopoulos; G Touloumi
Journal:  Hippokratia       Date:  2014-01       Impact factor: 0.471

Review 5.  Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.

Authors:  Filippo Ansaldi; Andrea Orsi; Laura Sticchi; Bianca Bruzzone; Giancarlo Icardi
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

6.  Effects of Nigella sativa on outcome of hepatitis C in Egypt.

Authors:  Eman Mahmoud Fathy Barakat; Lamia Mohamed El Wakeel; Radwa Samir Hagag
Journal:  World J Gastroenterol       Date:  2013-04-28       Impact factor: 5.742

Review 7.  Best strategies for global HCV eradication.

Authors:  Liesl M Hagan; Raymond F Schinazi
Journal:  Liver Int       Date:  2013-02       Impact factor: 5.828

8.  In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.

Authors:  Chunfu Wang; Lingling Jia; Haichang Huang; Dike Qiu; Lourdes Valera; Xin Huang; Jin-Hua Sun; Peter T Nower; Donald R O'Boyle; Min Gao; Robert A Fridell
Journal:  Antimicrob Agents Chemother       Date:  2011-12-27       Impact factor: 5.191

9.  NS5A sequence heterogeneity of hepatitis C virus genotype 4a predicts clinical outcome of pegylated-interferon-ribavirin therapy in Egyptian patients.

Authors:  Ahmed El-Shamy; Ikuo Shoji; Wafaa El-Akel; Shymaa E Bilasy; Lin Deng; Maissa El-Raziky; Da-peng Jiang; Gamal Esmat; Hak Hotta
Journal:  J Clin Microbiol       Date:  2012-09-19       Impact factor: 5.948

10.  Phylogenetic analysis of isolated HCV strains from tunisian hemodialysis patients.

Authors:  Fatma Houissa Kchouk; Yousr Gorgi; Lamjed Bouslama; Imen Sfar; Rym Ayari; Hacene Khiri; Phillipe Halfon; Houda Aouadi; Saloua Jendoubi Ayed; Khaled Ayed; Taieb Ben Abdallah
Journal:  Viral Immunol       Date:  2013-02-01       Impact factor: 2.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.